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ABSTRACT
Iron chelation therapy is used to reduce iron overload development due to its deposition in various organs 
such as liver and heart after regular transfusion. In this review, different iron chelators implicated in treatment
of iron overload in various clinical conditions have been evaluated using more up-to-date studies focusing on 
these therapeutic agents. Deferoxamine, Deferiprone and Deferasirox are the most important specific US FDA-
approved iron chelators. Each of these chelators has their own advantages and disadvantages, various target 
diseases, levels of deposited iron and clinical symptoms of the afflicted patients which may affect their 
selection as the best modality. Taken together, in many clinical disorders, choosing a standard chelator does 
not have an accurate index which requires further clarifications. The aim of this review is to introduce and 
compare the different iron chelators regarding their advantages and disadvantages, usage dose and specific 
applications.
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INTRODUCTION
   Iron is one of the essential elements in body 
which its concentration is tightly regulated. Iron 
overload during iron deposition in multiple organs is 
along with serum ferriƟn value over than 1000 
µg/L.1 Iron overload, either genetically or acquired, 
may occur by several conditions such as frequent 
transfusions, abuse consumption of iron (often as 
supplement) and chronic hepatitis have potential to 
cause acquired iron overload.2-3 Among genetic 
disorders that causes iron overload including
hereditary hemochromatosis (all types), African iron 
overload, sickle cell disease, major beta-
thalassemia, sideroblastic anemia, enzyme 
deĮciency (pyruvate kinase, G6PD) and rare 
disorders of transporting proteins 
(Atransferrinemia, Aceruloplasminemia),3-8
hereditary hemochromatosis is the most common 
genetic causes of iron overload.9 Small intestine in 
patient absorbs high level iron which accumulates in 
liver, pancreas and some parts of brain which 
results to impair vital functions.10 Free radical 
